Ci Investments Inc. Bei Gene, Ltd. Transaction History

Ci Investments Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$215.53 - $274.5 $11,638 - $14,823	54 Added 10.42%	572 $123,000
Q4 2022 Feb 10, 2023	BUY	$125.51 - $229.3 $48,572 - $88,739	387 Added 295.42%	518 $114,000
Q3 2022 Nov 14, 2022	SELL	$131.8 - $202.24 $659 - $1,011	-5 Reduced 3.68%	131 $18,000
Q2 2022 Aug 12, 2022	BUY	$121.11 - $216.05 $7,629 - $13,611	63 Added 86.3%	136 $22,000
Q3 2021 Nov 12, 2021	BUY	$249.6 - $403.14 $3,244 - $5,240	13 Added 21.67%	73 $26,000
Q1 2021 May 13, 2021	BUY	$260.64 - $382.12 $5,212 - $7,642	20 Added 50.0%	60 $21,000
Q4 2020 Feb 09, 2021	BUY	$221.31 - $316.61 $4,426 - $6,332	20 Added 100.0%	40 $10,000
Q3 2020 Nov 09, 2020	BUY	$189.18 - $286.44 $3,783 - $5,728	20 New	20 $6,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $22.3B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Ci Investments Inc., based on Form 13F filings with the SEC.

Stay updated on Ci Investments Inc. with notifications on news.